Literature DB >> 24440206

Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model.

Mahamoud Sama Cherif1, Mohammed Nasir Shuaibu2, Yukinobu Kodama3, Tomoaki Kurosaki3, Gideon Kofi Helegbe4, Mihoko Kikuchi4, Akitoyo Ichinose5, Tetsuo Yanagi6, Hitoshi Sasaki7, Katsuyuki Yui8, Nguyen Huy Tien9, Juntra Karbwang9, Kenji Hirayama10.   

Abstract

We have previously reported the new formulation of polyethylimine (PEI) with gamma polyglutamic acid (γ-PGA) nanoparticle (NP) to have provided Plasmodium yoelii merozoite surface protein-1 (PyMSP-1) plasmid DNA vaccine with enhanced protective cellular and humoral immunity in the lethal mouse malaria model. PyGPI8p-transamidase-related protein (PyTAM) was selected as a possible candidate vaccine antigen by using DNA vaccination screening from 29 GPI anchor and signal sequence motif positive genes picked up using web-based bioinformatics tools; though the observed protection was not complete. Here, we observed augmented protective effect of PyTAM DNA vaccine by using PEI and γ-PGA complex as delivery system. NP-coated PyTAM plasmid DNA immunized mice showed a significant survival rate from lethal P. yoelii challenge infection compared with naked PyTAM plasmid or with NP-coated empty plasmid DNA group. Antigen-specific IgG1 and IgG2b subclass antibody levels, proportion of CD4 and CD8T cells producing IFN-γ in the splenocytes and IL-4, IFN-γ, IL-12 and TNF-α levels in the sera and in the supernatants from ex vivo splenocytes culture were all enhanced by the NP-coated PyTAM DNA vaccine. These data indicates that NP augments PyTAM protective immune response, and this enhancement was associated with increased DC activation and concomitant IL-12 production.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA vaccine; GPI8p-transamidase; Gamma polyglutamic acid (γ-PGA); Nanoparticle; Plasmodium yoelii; Polyethylimine (PEI)

Mesh:

Substances:

Year:  2014        PMID: 24440206     DOI: 10.1016/j.vaccine.2014.01.005

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

Review 1.  The case for a rational genome-based vaccine against malaria.

Authors:  Carla Proietti; Denise L Doolan
Journal:  Front Microbiol       Date:  2015-01-22       Impact factor: 5.640

Review 2.  Polyethylenimine-based micro/nanoparticles as vaccine adjuvants.

Authors:  Chen Shen; Jun Li; Yi Zhang; Yuce Li; Guanxin Shen; Jintao Zhu; Juan Tao
Journal:  Int J Nanomedicine       Date:  2017-07-31

3.  Evaluation of transgene expression characteristics and DNA vaccination against melanoma metastasis of an intravenously injected ternary complex with biodegradable dendrigraft poly-L-lysine in mice.

Authors:  Yukinobu Kodama; Ayako Tokunaga; Junya Hashizume; Hiroo Nakagawa; Hitomi Harasawa; Tomoaki Kurosaki; Tadahiro Nakamura; Koyo Nishida; Mikiro Nakashima; Mitsuru Hashida; Shigeru Kawakami; Hitoshi Sasaki
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 4.  The Use of Synthetic Carriers in Malaria Vaccine Design.

Authors:  Liam Powles; Sue D Xiang; Cordelia Selomulya; Magdalena Plebanski
Journal:  Vaccines (Basel)       Date:  2015-10-29

Review 5.  Transmission-blocking strategies: the roadmap from laboratory bench to the community.

Authors:  Daniel Gonçalves; Patrick Hunziker
Journal:  Malar J       Date:  2016-02-18       Impact factor: 2.979

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.